Therapeutic Approach to Alzheimer’s Disease: Current Treatments and New Perspectives
Open accessThe DOI matches its Crossref record; 155 of the 158 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is the most common cause of dementia. The pathophysiology of this disease is characterized by the accumulation of amyloid-β, leading to the formation of senile plaques, and by the intracellular presence of neurofibrillary tangles based on hyperphosphorylated tau protein. In the therapeutic approach to AD, we can identify three important fronts: the approved drugs currently available for the treatment of the disease, which include aducanumab, donepezil, galantamine, rivastigmine, memantine, and a combination of memantine and donepezil; therapies under investigation that work mainly on Aβ pathology and tau pathology, and which include γ-secretase inhibitors, β-secretase inhibitors, α-secretase modulators, aggregation inhibitors, metal interfering drugs, drugs that enhance Aβ clearance, inhibitors of tau protein hyperphosphorylation, tau protein aggregation inhibitors, and drugs that promote the clearance of tau, and finally, other alternative therapies designed to improve lifestyle, thus contributing to the prevention of the disease. Therefore, the aim of this review was to analyze and describe current treatments and possible future alternatives in the therapeutic approach to AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It modulates glutamate transmission and dopamine receptors, exhibiting certain efficacy in improving patients’ cognitive function, daily living abilities, and behavior.409,410”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [410]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Donepezil, galantamine, and rivastigmine are the cholinesterase inhibitors that are most frequently prescribed [102,103,104,105,106].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [103]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The global prevalence of dementia: a systematic review and metaanalysis.
Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W., & Ferri, C. P. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.007 · Cited by 4,941
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 1×
“This study showed a dose-time-dependent reduction in Aβ plaques and an improvement in clinical manifestations of AD, as assessed by the Clinical Dementia RatingSum of Boxes (CDR-SB) and Mini Mental State Examination (MMSE) scores for the highest dose [20].”
MethodCraft, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.233 · Cited by 1,253
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
McShane, R., Areosa Sastre, A., & Minakaran, N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub5 · Cited by 1,155
Tau-targeting therapies for Alzheimer disease
Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113 · cited 2×
“However, despite the good results obtained in in vivo studies, no improvement in cognitive status, and no reduction of tau in the CSF of patients under treatment was observed [104,105].”
BackgroundTrial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049 · cited 1×
“A phase 2 study involving individuals with prodromal AD, and a phase 3 clinical trial studying the efficacy of this treatment at disease onset are currently underway [100,101].”
BackgroundBeneficial effects of physical exercise on neuroplasticity and cognition
Hötting, K., & Röder, B. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.04.005 · Cited by 991
Current and Future Treatments in Alzheimer Disease: An Update
Yiannopoulou, K. G., & Papageorgiou, S. G. (2020) · Journal of Central Nervous System Disease · doi:10.1177/1179573520907397 · Cited by 966 · cited 3×
“In one phase 3 clinical trial, participants with mild and moderate AD showed good tolerability, but no decrease in cognitive and functional impairment [75].”
BackgroundInfluentialA 5-month, randomized, placebo-controlled trial of galantamine in AD
Tariot, P. N., Solomon, P. R., Morris, J. C., Kershaw, P., Lilienfeld, S., Ding, C., & the Galantamine USA- Study Group (2000) · Neurology · doi:10.1212/wnl.54.12.2269 · Cited by 921
Mechanisms linking circadian clocks, sleep, and neurodegeneration
Musiek, E. S., & Holtzman, D. M. (2016) · Science · doi:10.1126/science.aah4968 · Cited by 878
Alzheimer's disease drug development pipeline: 2019
Cummings, J., Lee, G., Ritter, A., Sabbagh, M., & Zhong, K. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.05.008 · Cited by 762
Emerging roles of oxidative stress in brain aging and Alzheimer's disease
Ionescu-Tucker, A., & Cotman, C. W. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.07.014 · Cited by 737
Current and future treatments for Alzheimer's disease
Yiannopoulou, K. G., & Papageorgiou, S. G. (2013) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285612461679 · Cited by 677 · cited 1×
“Another etiological factor related to the development of AD is dyshomeostasis, or abnormal accumulation of metal ions such as copper, iron, or zinc [76].”
BackgroundSchneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12191 · Cited by 651
Salloway, S., Chalkias, S., Barkhof, F., Burkett, P., Barakos, J., Purcell, D., Suhy, J., Forrestal, F., Tian, Y., Umans, K., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2021.4161 · Cited by 619
TGF-β/BMP signaling and other molecular events: regulation of osteoblastogenesis and bone formation
Rahman, M. S., Akhtar, N., Jamil, H. M., Banik, R. S., & Asaduzzaman, S. M. (2015) · Bone Research · doi:10.1038/boneres.2015.5 · Cited by 587
Implications of sleep disturbance and inflammation for Alzheimer's disease dementia
Irwin, M. R., & Vitiello, M. V. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30450-2 · Cited by 578
A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
for the SCarlet RoAD Investigators, Ostrowitzki, S., Lasser, R. A., Dorflinger, E., Scheltens, P., Barkhof, F., Nikolcheva, T., Ashford, E., Retout, S., Hofmann, C., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0318-y · Cited by 567 · cited 1×
“A phase 2 study involving individuals with prodromal AD, and a phase 3 clinical trial studying the efficacy of this treatment at disease onset are currently underway [100,101].”
BackgroundRandomized trial of verubecestat for prodromal Alzheimer's disease
Egan, M. F., Kost, J., Voss, T., Mukai, Y., Aisen, P. S., Cummings, J. L., Tariot, P. N., Vellas, B., van Dyck, C. H., Boada, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812840 · Cited by 545
Rivastigmine for Alzheimer’s disease.
Birks, J. S., Chong, L.-Y., & Grimley Evans, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191.pub4 · Cited by 534
Román, G. C., Jackson, R. E., Gadhia, R., Román, A. N., & Reis, J. (2019) · Revue Neurologique · doi:10.1016/j.neurol.2019.08.005 · Cited by 421
Preventive Effects of Ramelteon on Delirium: A Randomized Placebo-Controlled Trial
Hatta, K., Kishi, Y., Wada, K., Takeuchi, T., Odawara, T., Usui, C., & Nakamura, H. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.3320 · Cited by 369
Tacrine in Alzheimer's disease
Eagger, S. A., Levy, R., & Sahakian, B. J. (1991) · The Lancet · doi:10.1016/0140-6736(91)92656-m · Cited by 361
Amyloid-Beta Protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimer’s Disease
Baranello, R., Bharani, K., Padmaraju, V., Chopra, N., Lahiri, D., Greig, N., Pappolla, M., & Sambamurti, K. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666141218140953 · Cited by 331 · cited 1×
“Therefore, it has been proposed that alterations in Aβ degradation or clearance may also play a key role in the pathogenesis of AD [6].”
BackgroundDonepezil for the Treatment of Agitation in Alzheimer's Disease
Howard, R. J., Juszczak, E., Ballard, C. G., Bentham, P., Brown, R. G., Bullock, R., Burns, A. S., Holmes, C., Jacoby, R., Johnson, T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066583 · Cited by 327
The essential elements of Alzheimer’s disease
Lei, P., Ayton, S., & Bush, A. I. (2021) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.008207 · Cited by 327
Dowling, G. A., Burr, R. L., Van Someren, E. J. W., Hubbard, E. M., Luxenberg, J. S., Mastick, J., & Cooper, B. A. (2008) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2007.01543.x · Cited by 313
McShane, R., Westby, M. J., Roberts, E., Minakaran, N., Schneider, L., Farrimond, L. E., Maayan, N., Ware, J., & Debarros, J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub6 · Cited by 310
Current and future treatments in Alzheimer’s disease
Atri, A. (2019) · Seminars in Neurology · doi:10.1055/s-0039-1678581 · Cited by 309
Zucchella, C., Sinforiani, E., Tamburin, S., Federico, A., Mantovani, E., Bernini, S., Casale, R., & Bartolo, M. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.01058 · Cited by 297
Alzheimer’s disease: pathological mechanisms and the beneficial role of melatonin
Rosales‐Corral, S. A., Acuña‐Castroviejo, D., Coto‐Montes, A., Boga, J. A., Manchester, L. C., Fuentes‐Broto, L., Korkmaz, A., Ma, S., Tan, D. X., & Reiter, R. J. (2012) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2011.00937.x · Cited by 294
Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues
Brambilla, D., Le Droumaguet, B., Nicolas, J., Hashemi, S. H., Wu, L.-P., Moghimi, S. M., Couvreur, P., & Andrieux, K. (2011) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2011.03.008 · Cited by 294
Decreased plasma antioxidants in patients with Alzheimer's disease
Kim, T.-S., Pae, C.-U., Yoon, S.-J., Jang, W.-Y., Lee, N. J., Kim, J.-J., Lee, S.-J., Lee, C., Paik, I.-H., & Lee, C.-U. (2006) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1469 · Cited by 291
Immunotherapeutic Approaches for Alzheimer’s Disease
Wisniewski, T., & Goñi, F. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.064 · Cited by 284 · cited 1×
“This group of drugs belongs to the immunotherapeutic approach and includes two possible modalities: active and passive immunotherapy [94].”
BackgroundA phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Keren, R., Porsteinsson, A. P., van Dyck, C. H., Tariot, P. N., Gilman, S., Arnold, D., Abushakra, S., Hernandez, C., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182309fa5 · Cited by 258
Seltzer, B. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.7.1011 · Cited by 256
The impact of diabetes on cognitive impairment and its progression to dementia
Dove, A., Shang, Y., Xu, W., Grande, G., Laukka, E. J., Fratiglioni, L., & Marseglia, A. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12482 · Cited by 252
Rivastigmine for Alzheimer's disease
Birks, J. S., & Grimley Evans, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191.pub3 · Cited by 247
Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial
Coric, V., Salloway, S., van Dyck, C. H., Dubois, B., Andreasen, N., Brody, M., Curtis, C., Soininen, H., Thein, S., Shiovitz, T., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.0607 · Cited by 240
Muntimadugu, E., Dhommati, R., Jain, A., Challa, V. G. S., Shaheen, M., & Khan, W. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.05.012 · Cited by 240
Karthivashan, G., Ganesan, P., Park, S.-Y., Kim, J.-S., & Choi, D.-K. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1428243 · Cited by 223
On the early diagnosis of Alzheimer's Disease from multimodal signals: A survey
Alberdi, A., Aztiria, A., & Basarab, A. (2016) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2016.06.003 · Cited by 221
Inflammation, Antiinflammatory Agents, and Alzheimer’s Disease: The Last 22 Years
McGeer, P. L., Rogers, J., & McGeer, E. G. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160488 · Cited by 215
Lu, Y., Dong, Y., Tucker, D., Wang, R., Ahmed, M. E., Brann, D., & Zhang, Q. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160869 · Cited by 214
Review of Current Strategies for Delivering Alzheimer’s Disease Drugs across the Blood-Brain Barrier
Wong, K. H., Riaz, M. K., Xie, Y., Zhang, X., Liu, Q., Chen, H., Bian, Z., Chen, X., Lu, A., & Yang, Z. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020381 · Cited by 213
Um, H.-S., Kang, E.-B., Koo, J.-H., Kim, H.-T., Jin-Lee, Kim, E.-J., Yang, C.-H., An, G.-Y., Cho, I.-H., & Cho, J.-Y. (2011) · Neuroscience Research · doi:10.1016/j.neures.2010.10.004 · Cited by 212
Physical Training Improves Motor Performance in People with Dementia: A Randomized Controlled Trial
Hauer, K., Schwenk, M., Zieschang, T., Essig, M., Becker, C., & Oster, P. (2012) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03778.x · Cited by 212
Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer’s Disease
Henley, D., Raghavan, N., Sperling, R., Aisen, P., Raman, R., & Romano, G. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1813435 · Cited by 197
Recent Progress in Alzheimer’s Disease Research, Part 3: Diagnosis and Treatment
Hane, F. T., Robinson, M., Lee, B. Y., Bai, O., Leonenko, Z., & Albert, M. S. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160907 · Cited by 197
Li, Y., Zhang, J., Wan, J., Liu, A., & Sun, J. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110887 · Cited by 197
Early-Onset Alzheimer’s Disease: What Is Missing in Research?
Ayodele, T., Rogaeva, E., Kurup, J. T., Beecham, G., & Reitz, C. (2021) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-020-01090-y · Cited by 193
Nascimento, C., Pereira, J., Andrade, L., Garuffi, M., Talib, L., Forlenza, O., Cancela, J., Cominetti, M., & Stella, F. (2014) · Current Alzheimer Research · doi:10.2174/156720501108140910122849 · Cited by 192
Plascencia-Villa, G., & Perry, G. (2021) · Antioxidants & Redox Signaling · doi:10.1089/ars.2020.8134 · Cited by 188
Haake, A., Nguyen, K., Friedman, L., Chakkamparambil, B., & Grossberg, G. T. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1721456 · Cited by 181
Li, D.-D., Zhang, Y.-H., Zhang, W., & Zhao, P. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00472 · Cited by 180
Chainoglou, E., & Hadjipavlou‐Litina, D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061975 · Cited by 179
Galantamine for Alzheimer's disease
Loy, C., & Schneider, L. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001747.pub2 · Cited by 178
Polyphenols as Potential Metal Chelation Compounds Against Alzheimer’s Disease
Lakey-Beitia, J., Burillo, A. M., La Penna, G., Hegde, M. L., & Rao, K. S. (2021) · Journal of Alzheimer's Disease · doi:10.3233/jad-200185 · Cited by 177
Laudon, M., G Wade, A., Farmer, M., Harari, G., Fund, N., Nir, T., Frydman-Marom, A., & Zisapel, N. (2014) · Clinical Interventions in Aging · doi:10.2147/cia.s65625 · Cited by 173
Guo, J., Wang, Z., Liu, R., Huang, Y., Zhang, N., & Zhang, R. (2020) · Brain and Behavior · doi:10.1002/brb3.1831 · Cited by 165
Donepezil in Alzheimer’s disease: from conventional trials to pharmacogenetics
Cacabelos, R. (2007) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.a908 · Cited by 164
Cortical tau deposition follows patterns of entorhinal functional connectivity in aging
Adams, J. N., Maass, A., Harrison, T. M., Baker, S. L., & Jagust, W. J. (2019) · eLife · doi:10.7554/elife.49132 · Cited by 160
An Overview on the Clinical Development of Tau-Based Therapeutics
Medina, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041160 · Cited by 156
UB‐311, a novel UBITh ® amyloid β peptide vaccine for mild Alzheimer's disease
Wang, C. Y., Wang, P., Chiu, M., Finstad, C. L., Lin, F., Lynn, S., Tai, Y., De Fang, X., Zhao, K., Hung, C., et al. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.03.005 · Cited by 150
Wagstaff, A. J., & McTavish, D. (1994) · Drugs & Aging · doi:10.2165/00002512-199404060-00006 · Cited by 147
New Insights Into Drug Discovery Targeting Tau Protein
Soeda, Y., & Takashima, A. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.590896 · Cited by 146
Coelho, F. M., Pereira, D. S., Lustosa, L. P., da Silva, J. P., Dias, J. M. D., Dias, R. C., de Queiroz, B. Z., Teixeira, A. L., Teixeira, M. M., & Pereira, L. S. M. (2011) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2011.05.014 · Cited by 139
Winblad, B., Grossberg, G., Frölich, L., Farlow, M., Zechner, S., Nagel, J., & Lane, R. (2007) · Neurology · doi:10.1212/01.wnl.0000281847.17519.e0 · Cited by 136
Misra, S., Chopra, K., Sinha, V. R., & Medhi, B. (2016) · Drug Delivery · doi:10.3109/10717544.2015.1089956 · Cited by 136
Estimating the burden of early onset dementia; systematic review of disease prevalence
Lambert, M. A., Bickel, H., Prince, M. J., Fratiglioni, L., Strauss, E. I. V., Frydecka, D., Kiejna, A., Georges, J., & Reynish, E. L. (2014) · European Journal of Neurology · doi:10.1111/ene.12325 · Cited by 135
Clinical Pharmacokinetics of Galantamine
Farlow, M. R. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342150-00005 · Cited by 134 · cited 1×
“In addition, it stimulates the intrinsic action of acetylcholine on nicotinic receptors [42].”
BackgroundEHT0202 in Alzheimers Disease: A 3-Month, Randomized, Placebo- Controlled, Double-Blind Study
Vellas, B., Sol, O., J. Snyder, P., Ousset, P.-J., Haddad, R., Maurin, M., Lemarie, J.-C., Desire, L., & P. Pando, M. (2011) · Current Alzheimer Research · doi:10.2174/156720511795256053 · Cited by 133
Removing endogenous tau does not prevent tau propagation yet reduces its neurotoxicity
Wegmann, S., Maury, E. A., Kirk, M. J., Saqran, L., Roe, A., DeVos, S. L., Nicholls, S., Fan, Z., Takeda, S., Cagsal‐Getkin, O., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201592748 · Cited by 132
Investigational BACE inhibitors for the treatment of Alzheimer’s disease
Imbimbo, B. P., & Watling, M. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1683160 · Cited by 132
Folch, J., Ettcheto, M., Petrov, D., Abad, S., Pedrós, I., Marin, M., Olloquequi, J., & Camins, A. (2015) · Neurología · doi:10.1016/j.nrl.2015.03.012 · Cited by 131
Folch, J., Ettcheto, M., Petrov, D., Abad, S., Pedrós, I., Marin, M., Olloquequi, J., & Camins, A. (2017) · Neurología (English Edition) · doi:10.1016/j.nrleng.2015.03.019 · Cited by 129
Gonzalez-Carter, D., Liu, X., Tockary, T. A., Dirisala, A., Toh, K., Anraku, Y., & Kataoka, K. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2002016117 · Cited by 127
Xie, J., Carter, D. A. G., Tockary, T. A., Nakamura, N., Xue, Y., Nakakido, M., Akiba, H., Dirisala, A., Liu, X., Toh, K., et al. (2020) · ACS Nano · doi:10.1021/acsnano.9b09991 · Cited by 122
Mowla, A., Mosavinasab, M., Haghshenas, H., & Haghighi, A. B. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31814b98c1 · Cited by 116
Lopez Lopez, C., Tariot, P. N., Caputo, A., Langbaum, J. B., Liu, F., Riviere, M., Langlois, C., Rouzade‐Dominguez, M., Zalesak, M., Hendrix, S., et al. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.02.005 · Cited by 116
Side effects of approved antidementives.
Mimica, N., & Presečki, P. (2009) · PubMed · Cited by 114
SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study
Maher‐Edwards, G., Dixon, R., Hunter, J. A., Gold, M., Hopton, G., Jacobs, G., Hunter, J., & Williams, P. M. (2010) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2562 · Cited by 113
Lacosta, A.-M., Pascual-Lucas, M., Pesini, P., Casabona, D., Pérez-Grijalba, V., Marcos-Campos, I., Sarasa, L., Canudas, J., Badi, H., Monleón, I., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0340-8 · Cited by 111
Effect of Tacrine on Language, Praxis, and Noncognitive Behavioral Problems in Alzheimer Disease
Raskind, M. A., Sadowsky, C. H., Sigmund, W. R., Beitler, P., & Auster, S. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550190026010 · Cited by 111
Galantamine for dementia due to Alzheimer's disease
Olin, J. T., & Schneider, L. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001747 · Cited by 108
Feldman, H. H., Lane, R., & on behalf of the Study 304 Group (2007) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.099424 · Cited by 107
Shabani, A., Foroozanfard, F., Kavossian, E., Aghadavod, E., Ostadmohammadi, V., Reiter, R. J., Eftekhar, T., & Asemi, Z. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.02.066 · Cited by 106
García-Morales, V., González-Acedo, A., Melguizo-Rodríguez, L., Pardo-Moreno, T., Costela-Ruiz, V. J., Montiel-Troya, M., & Ramos-Rodríguez, J. J. (2021) · Biomedicines · doi:10.3390/biomedicines9121910 · Cited by 104
Self-citationHanafy, A. S., Farid, R. M., Helmy, M. W., & ElGamal, S. S. (2016) · Drug Delivery · doi:10.3109/10717544.2016.1153748 · Cited by 101
van Opstal, A. M., van Rooden, S., van Harten, T. W., Ghariq, E., Labadie, G., Fotiadis, P., Gurol, M. E., Terwindt, G. M., Wermer, M. J. H., van Buchem, M. A., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30346-5 · Cited by 95
Boada, M., Anaya, F., Ortiz, P., Olazarán, J., Shua-Haim, J. R., Obisesan, T. O., Hernández, I., Muñoz, J., Buendia, M., Alegret, M., et al. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160565 · Cited by 94
BACE inhibitors in clinical development for the treatment of Alzheimer’s disease
Panza, F., Lozupone, M., Solfrizzi, V., Sardone, R., Piccininni, C., Dibello, V., Stallone, R., Giannelli, G., Bellomo, A., Greco, A., et al. (2018) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2018.1531706 · Cited by 92
Homma, A., Imai, Y., Tago, H., Asada, T., Shigeta, M., Iwamoto, T., Takita, M., Arimoto, I., Koma, H., & Ohbayashi, T. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000122961 · Cited by 92
Xu, P., Zhang, M., Sheng, R., & Ma, Y. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.12.045 · Cited by 92
Does Music Therapy Improve Anxiety and Depression in Alzheimer's Patients?
Ortí, J. E. D. L. R., García-Pardo, M. P., Iranzo, C., Cerón, J. M. C., Sancho-Castillo, S., Rochina, M. J., & Prado‐Gascó, V. (2017) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2016.0346 · Cited by 91
Critical Appraisal of Amyloid Lowering Agents in AD
Decourt, B., Boumelhem, F., Pope, E. D., Shi, J., Mari, Z. K., & Sabbagh, M. N. (2021) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-021-01125-y · Cited by 90
Regulation of neuronal microtubule dynamics by tau: Implications for tauopathies
Venkatramani, A., & Panda, D. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.04.120 · Cited by 88
Almkvist, O., Jelić, V., Amberla, K., Hellström‐Lindahl, E., Meurling, L., & Nordberg, A. K. (2000) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000051232 · Cited by 88
Gutzmann, H., Kühl, K.-P., Hadler, D., & Rapp, M. A. (2002) · Pharmacopsychiatry · doi:10.1055/s-2002-19833 · Cited by 85
Analysis of in vivo turnover of tau in a mouse model of tauopathy
Yamada, K., Patel, T. K., Hochgräfe, K., Mahan, T. E., Jiang, H., Stewart, F. R., Mandelkow, E., & Holtzman, D. M. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0052-5 · Cited by 82
Kellar, D., Register, T. C., Lockhart, S. N., Aisen, P. S. S., Raman, R., Rissman, R. A., Brewer, J. B., & Craft, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-05165-3 · Cited by 80
Nanocarrier mediated drug delivery as an impeccable therapeutic approach against Alzheimer’s disease
Taliyan, R., Kakoty, V., Sarathlal, K. C., Kharavtekar, S. S., Karennanavar, C. R., Choudhary, Y. K., Singhvi, G., Riadi, Y., Dubey, S. K., & Kesharwani, P. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.044 · Cited by 80
Donepezil: potential neuroprotective and disease-modifying effects
Jacobson, S. A., & Sabbagh, M. N. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.10.1363 · Cited by 78
Use of memantine for the treatment of dementia
Lo, D. T., & Grossberg, G. T. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.132 · Cited by 75
Ramos‐Rodríguez, J. J., Spires‐Jones, T. L., Pooler, A. M., Lechuga-Sancho, A. M., Bacskai, B. J., & García-Alloza, M. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9921-3 · Cited by 71
Self-citationKim, D.-J. (2020) · Occupational Therapy International · doi:10.1155/2020/6305727 · Cited by 71
Rivastigmine for Alzheimer’s disease
Desai, A. K., & Grossberg, G. T. (2005) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.5.5.563 · Cited by 70
Knapp, M. R. J., King, D., Romeo, R., Adams, J., Baldwin, A., Ballard, C. G., Banerjee, S., Barber, R., Bentham, P., Brown, R. G., et al. (2016) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4583 · Cited by 69
Exercise decreases BACE and APP levels in the hippocampus of a rat model of Alzheimer's disease
Alkadhi, K. A., & Dao, A. T. (2017) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2017.11.008 · Cited by 68
Prevention and Treatment of Alzheimer’s Disease: Biological Mechanisms of Exercise
McGurran, H., Glenn, J. M., Madero, E. N., & Bott, N. T. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180958 · Cited by 66
Karaman, Y., Erdoğan, F., Köseoğlu, E., Turan, T., & Ersoy, A. Ö. (2005) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000080972 · Cited by 66
An evaluation of memantine ER + donepezil for the treatment of Alzheimer’s disease
Calhoun, A. J., King, C., Khoury, R., & Grossberg, G. T. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1519022 · Cited by 65
Sita, G., Hrelia, P., Tarozzi, A., & Morroni, F. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091454 · Cited by 65
Hull, M., Sadowsky, C., Arai, H., Leterme, G. L. P., Holstein, A., Booth, K., Peng, Y., Yoshiyama, T., Suzuki, H., Ketter, N., et al. (2017) · Current Alzheimer Research · doi:10.2174/1567205014666170117101537 · Cited by 65 · cited 1×
“In the case of ACC-001, this was administered in subjects with mild to moderate AD, with higher Ig G and anti-Aβ40 levels than in the other groups [97].”
Lithium as a Treatment for Alzheimer’s Disease: The Systems Pharmacology Perspective
Hampel, H., Lista, S., Mango, D., Nisticò, R., Perry, G., Avila, J., Hernandez, F., Geerts, H., Vergallo, A., (APMI), A. P. M. I., et al. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-190197 · Cited by 65
Guthrie, H., Honig, L. S., Lin, H., Sink, K. M., Blondeau, K., Quartino, A., Dolton, M., Carrasco-Triguero, M., Lian, Q., Bittner, T., et al. (2020) · Journal of Alzheimer’s Disease · doi:10.3233/jad-200134 · Cited by 65
Robinson, M. M., Lowe, V. J., & Nair, K. S. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01571 · Cited by 62
Vincent, B. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.06.011 · Cited by 58
Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease
Seltzer, B. (2009) · Clinical Interventions in Aging · doi:10.2147/cia.s4819 · Cited by 57
The Pharmacoeconomics of Cognitive Enhancers in Moderate to Severe Alzheimerʼs Disease
Cappell, J., Herrmann, N., Cornish, S., & Lanctôt, K. L. (2010) · CNS Drugs · doi:10.2165/11539530-000000000-00000 · Cited by 57
Nakamura, Y., Imai, Y., Shigeta, M., Graf, A., Shirahase, T., Kim, H., Fujii, A., Mori, J., & Homma, A. (2011) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000328929 · Cited by 57
Weycker, D., Taneja, C., Edelsberg, J., Haim Erder, M., Schmitt, F. A., Setyawan, J., & Oster, G. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x188071 · Cited by 52
Nutritional interventions for Alzheimer's prevention: a clinical precision medicine approach
Schelke, M. W., Hackett, K., Chen, J. L., Shih, C., Shum, J., Montgomery, M. E., Chiang, G. C., Berkowitz, C., Seifan, A., Krikorian, R., et al. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13070 · Cited by 51
A rivastigmine patch for the treatment of Alzheimer’s disease and Parkinson’s disease dementia
Cummings, J. L., & Winblad, B. G. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.11.1457 · Cited by 50
Wahba, S. M. R., Darwish, A. S., & Kamal, S. M. (2016) · Materials Science and Engineering C · doi:10.1016/j.msec.2016.04.041 · Cited by 50
Galantamine and behavior in Alzheimer disease: analysis of four trials
Kavanagh, S., Gaudig, M., van Baelen, B., Adami, M., Delgado, A., Guzman, C., Jedenius, E., & Schäuble, B. (2011) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2011.01525.x · Cited by 48
Sankar, S. B., Infante-Garcia, C., Weinstock, L. D., Ramos-Rodriguez, J. J., Hierro-Bujalance, C., Fernandez-Ponce, C., Wood, L. B., & Garcia-Alloza, M. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-1707-x · Cited by 46
Self-citationAlzheimer’s disease research: The future of BACE inhibitors
Burki, T. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31425-9 · Cited by 40
Perche, F., Uchida, S., Akiba, H., Lin, C., Ikegami, M., Dirisala, A., Nakashima, T., Itaka, K., Tsumoto, K., & Kataoka, K. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666161108110031 · Cited by 37
Jia, J., Wei, C., Jia, L., Tang, Y., Liang, J., Zhou, A., Li, F., Shi, L., & Doody, R. S. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161117 · Cited by 37
Pluta, R. M., Ouyang, L., Januszewski, S., Li, Y., & Czuczwar, S. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052460 · Cited by 37
Efficacy and tolerability of memantine in the treatment of dementia
Rossom, R. C., Adityanjee, & Dysken, M. W. (2004) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2004.12.006 · Cited by 36
Portugal, E. M. M., Vasconcelos, P., de Souza, R. M., Lattari, E., Monteiro-Júnior, R. S., Machado, S. E. D. C., & Deslandes, A. C. (2015) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527315666151111121749 · Cited by 36
Xu, L., Yu, H., Sun, H., Hu, B., & Geng, Y. (2020) · Medical Science Monitor · doi:10.12659/msm.923232 · Cited by 35
Melatonin and Sleep Disturbances in Alzheimer’s Disease
Prodhan, A. H. M. S. U., Cavestro, C., Kamal, M. A., & Islam, M. A. (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527320666210804155617 · Cited by 34
Homma, A., Atarashi, H., Kubota, N., Nakai, K., & Takase, T. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151149 · Cited by 33
mg), O. B. O. T. O. S. (. D. E. S. T. S. A. O. H. D. D. 2., Hong, Y. J., Han, H. J., Youn, Y. C., Park, K. W., Yang, D. W., Kim, S., Kim, H. J., Kim, J. E., & Lee, J. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0492-1 · Cited by 32
The acute hepatotoxicity of tacrine explained by1H NMR based metabolomic profiling
Lou, Y.-H., Wang, J., Dong, G., Guo, P.-P., Wei, D., Xie, S., Yang, M., & Kong, L. (2015) · Toxicology Research · doi:10.1039/c5tx00096c · Cited by 31
Jarrott, B. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2016.12.033 · Cited by 30
Cruz‐Aguilar, M. A., Ramírez‐Salado, I., Guevara, M. Á., González, M. H., & Benítez‐King, G. (2018) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-170019 · Cited by 29
Yunusa, I. U., Alsahali, S. M., Rane, A., & Eguale, T. (2021) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-210307 · Cited by 22
γ-AApeptides as a New Strategy for Therapeutic Development
Nimmagadda, A., Shi, Y., & Cai, J. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867324666171107095913 · Cited by 21 · cited 1×
“The latter have yet to be tested in in vivo trials [90].”
BackgroundThe Role of Nutrition in Individualized Alzheimer’s Risk Reduction
Amini, Y., Saif, N., Greer, C. E., Hristov, H., & Isaacson, R. (2020) · Current Nutrition Reports · doi:10.1007/s13668-020-00311-7 · Cited by 21
A Double-Blind, Placebo-Controlled Study of Tacrine in Chinese Patients with Alzheimer’s Disease
Wong, W.-J., Liu, H.-C., Fuh, J., Wang, S., Hsu, L., Wang, P., & Sheng, W. (1999) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017134 · Cited by 20
Peptidomimetics That Inhibit and Partially Reverse the Aggregation of Aβ1–42
Stark, T., Lieblein, T., Pohland, M., Kalden, E., Freund, P., Zangl, R., Grewal, R., Heilemann, M., Eckert, G. P., Morgner, N., et al. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00223 · Cited by 17
Kartalou, G.-I., Endres, T., Leßmann, V., & Gottmann, K. (2020) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2020.108797 · Cited by 16
Krishnan, H. S., Bernard‐Gauthier, V., Placzek, M. S., Dahl, K., Narayanaswami, V., Livni, E., Chen, Z., Yang, J., Collier, T. L., Ran, C., et al. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00936 · Cited by 15
Li, H.-H., Yao, X.-Y., Tao, S., Sun, X., Li, P.-P., Li, X.-X., Liu, Z.-L., & Ren, C. (2021) · Behavioural Neurology · doi:10.1155/2021/5533827 · Cited by 13
Alzheimer's Disease, time to turn the tide
Sensi, S. L. (2018) · Aging · doi:10.18632/aging.101581 · Cited by 11
Untangling the tau microtubule-binding region
Toombs, J., & Zetterberg, H. (2020) · Brain · doi:10.1093/brain/awaa468 · Cited by 10
Is Alzheimer's Prevention Possible Today?
Isaacson, R. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15060 · Cited by 9
Kishimoto, Y., Shishido, H., Sawanishi, M., Toyota, Y., Ueno, M., Kubota, T., Kirino, Y., Tamiya, T., & Kawai, N. (2016) · Data in Brief · doi:10.1016/j.dib.2016.08.041 · Cited by 8
Barton, M. E., Byrnes, W., Mesa, I. R., Bloemers, J., Maguire, R. P., Bouw, R., Tesseur, I. C., Ewen, C., & Scheltens, P. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.057586 · Cited by 6
Research works printed but not linked: 1
- Buchanan, T., De Bruyn, S., Fadini, T., Watanabe, S., Germani, M., and Mesa, A.B.I.R. (2019, January 22–26). A Randomised, Placebo-Controlled, First-in-Human Study with a Central Tau Epitope Antibody–UCB0107. Proceedings of the International Congress of Parkinson’s Disease and Movement Disorders, Nice, France.
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Connelly‐Smith, L., Alquist, C. R., Aqui, N. A., Hofmann, J. C., Klingel, R., Onwuemene, O. A., Patriquin, C. J., Pham, H. P., Sanchez, A. P., Schneiderman, J., et al. (2023) · Journal of Clinical Apheresis · doi:10.1002/jca.22043 · Cited by 684
Multifunctional nanoparticle-mediated combining therapy for human diseases
Li, X., Peng, X., Zoulikha, M., Boafo, G. F., Magar, K. T., Ju, Y., & He, W. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01668-1 · Cited by 521
Singh, B., Day, C. M., Abdella, S., & Garg, S. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.047 · Cited by 228
Rahimi Darehbagh, R., Seyedoshohadaei, S. A., Ramezani, R., & Rezaei, N. (2024) · European Journal of Medical Research · doi:10.1186/s40001-024-01987-1 · Cited by 167
Metadata
- Authors
- Pardo-Moreno, T., González-Acedo, A., Rivas-Domínguez, A., García-Morales, V., García-Cozar, F. J., Ramos-Rodríguez, J. J., & Melguizo-Rodríguez, L.
- Affiliations
- Instituto Nacional de Gestión Sanitaria (INGESA), Primary Health Care, 51003 Ceuta, Spain
- Biomedical Group (BIO277), Department of Nursing, Faculty of Health Sciences (Melilla), University of Granada, 52005 Granada, Spain
- Universidad de Sevilla (ES)
- Department of Biomedicine, Biotechnology and Public Health, Physiology Area, Faculty of Medicine, University of Cádiz, Pl. Falla, 9, 11003 Cádiz, Spain
- Department of Biomedicine, Biotechnology and Public Health, Immunology Area, University of Cádiz Pl. Falla, 9, 11003 Cádiz, Spain
- Department of Physiology, Faculty of Health Sciences (Ceuta), University of Granada, 51001 Ceuta, Spain
- Biomedical Group (BIO277), Department of Nursing, Faculty of Health Sciences, University of Granada, 18016 Granada, Spain
- ORCID
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2022-05-24
- Volume
- 14
- Issue
- 6
- Pages
- 1117
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC9228613
- OpenAlex
- W4281488754
- Cited by
- 239
- References
- 158
- Citations by year
- 2026: 52 · 2025: 62 · 2024: 66 · 2023: 48 · 2022: 11
- FWCI
- 6.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Repository of the University of Granada (University of Granada) (submittedVersion, cc-by)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Deposito de Investigacion Universidad de Sevilla (University of Seville) (submittedVersion, cc-by)
- RODIN (Universidad de Cádiz) (submittedVersion, cc-by)
- Funders
- Junta de Andalucía, Spain (P20-01293, PECART-0096-2020, PID2020-117544RB-100)
- the Ministry of Science and Innovation, Spain (P20-01293, PECART-0096-2020, PID2020-117544RB-100)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, amyloid-beta, tau hyperphosphorylation, amyloid plaques, neurofibrillary tangles, aducanumab, donepezil, galantamine, rivastigmine, memantine, gamma-secretase inhibitors, beta-secretase inhibitors, aggregation inhibitors, amyloid-beta clearance, tau aggregation inhibitors, dementia treatment, lifestyle intervention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.